Astrazeneca ADR Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Astrazeneca ADR Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Astrazeneca ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | - | - | - | - | - | - | - |
| GSK plc ADR | -0.430% | -4.918% | -0.855% | 48.718% | 11.005% | 42.331% | 18.217% |
| Bayer AG ADR | -4.230% | -9.135% | -2.073% | 68.750% | 7.386% | -35.714% | -30.515% |
| Novartis AG ADR | 0.000% | -3.876% | -3.876% | 25.506% | 4.641% | 33.047% | 72.702% |
News
P&G and OMP Showcase the Path to Autonomous, Decision-Centric Planning at Gartner Supply Chain Symposium/Xpo 2026
How decision velocity is closing the gap between insight and action across one of the world's most complex value chains
ATLANTA, GA / ACCESS Newswire / April 14, 2026 / OMP, a leader in
As Investors Flee U.S. Equities, This Global ETF Is Outperforming
Since the start of the year, investors have been vacating U.S. stocks and exchange-traded funds (ETFs) in a broad-based, risk-off strategy that has benefited safe-haven assets like gold and silver
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI (NASDAQ: TEM) have gone on a wild rollercoaster ride. The firm’s initial public offering price